%0 Journal Article
%T Fluorescent In Situ Staining and Flow Cytometric Procedures as New Pre-Diagnostic Tests for Sialidosis, GM1 Gangliosidosis and Niemann-Pick Type C.
%A Capitini C
%A Feo F
%A Caciotti A
%A Tonin R
%A Lulli M
%A Coviello D
%A Guerrini R
%A Calamai M
%A Morrone A
%A Capitini C
%A Feo F
%A Caciotti A
%A Tonin R
%A Lulli M
%A Coviello D
%A Guerrini R
%A Calamai M
%A Morrone A
%A Capitini C
%A Feo F
%A Caciotti A
%A Tonin R
%A Lulli M
%A Coviello D
%A Guerrini R
%A Calamai M
%A Morrone A
%J Biomedicines
%V 10
%N 8
%D Aug 2022 12
%M 36009508
%F 4.757
%R 10.3390/biomedicines10081962
%X <B>BACKGROUND: </B>Early diagnosis is essential in the field of lysosomal storage disorders for the proper management of patients and for starting therapies before irreversible damage occurs, particularly in neurodegenerative conditions. Currently, specific biomarkers for the diagnosis of lysosomal storage disorders are lacking in routine laboratory practice, except for enzymatic tests, which are available only in specialized metabolic centers. Recently, we established a method for measuring and verifying changes in GM1 ganglioside levels in peripheral blood lymphocytes in patients with GM1 gangliosidosis. However, fresh blood is not always available, and using frozen/thawed lymphocytes can lead to inaccurate results.<BR><B>METHODS: </B>We used frozen/thawed fibroblasts obtained from stored biopsies to explore the feasibility of fluorescent imaging and flow-cytometric methods to track changes in storage materials in fibroblasts from patients with three lysosomal neurodegenerative conditions: GM1 gangliosidosis, Sialidosis, and Niemann-Pick type C. We used specific markers for each pathology.<BR><B>CONCLUSIONS: </B>We demonstrated that with our methods, it is possible to clearly distinguish the levels of accumulated metabolites in fibroblasts from affected and unaffected patients for all the three pathologies considered. Our methods proved to be rapid, sensitive, unbiased, and potentially applicable to other LSDs.